CHAMPION Brian Robert (GB),ЧЭМПИОН Брайан Роберт (GB),CONTILLO JR. Leonard Gabriel (US),КОНТИЛЛО Мл. Леонард Гэбриел (US),EISENBRAUN Michael Dale (US),ЭЙСЕНБРАУН Майкл Дейл (US),FRASER James Downey (U,CHAMPION BRIAN ROBERT,ЧЭМПИОН Брайан Роберт,CONTILLO JR. LEONARD GABRIEL,КОНТИЛЛО Мл. Леонард Гэбриел,EISENBRAUN MICHAEL DALE,ЭЙСЕНБРАУН Майкл Дейл,FRASER JAMES DOWNEY,ФРЕЙЗЕР Джеймс Дауни,HAWKINS JUL
申请号：
RU2012107657/10
公开号：
RU0002538162C2
申请日:
2010.08.23
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to immunology and biotechnology. Presented is an immunogen for inducing an immune response to the PCSK9 protein, containing the PCSK9 antigen peptide specified in a group consisting of the disclosed SEQ ID NO: 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 314, 318 and 319, containing the amino acid sequence TRFHRQ, and SEQ ID NO: 182, 183, 184, 185, 186, 187, 188, 317, 401, 402 and 403, containing the amino acid sequence SIPWNLE, wherein the above PCSK9 peptide is conjugated with an immunogenic carrier specified in CRM197 or a Qbeta viral-like particle (VLP). Described is a composition for inducing the immune response to the PCSK9 protein containing at least two immunogens in immunologically effective amounts, wherein the first immunogen represents the above immunogen. Disclosed is a composition for inducing the immune response to the PCSK9 protein containing at least two immunogens in the immunologically effective amounts, wherein the first immunogen is specified in a group of immunogens containing the amino acid sequence SIPWNLE, and wherein the second immunogen is specified in a group of immunogens containing the amino acid sequence TRFHRQ； and wherein the composition can additionally contain at least one adjuvant. What is also presented is a pharmaceutical composition for preventing, treating or relieving PCSK9-related disorders containing: the above immunogen in a therapeutically effective amount, or one of the above compositions, and a pharmaceutically acceptable excipient.EFFECT: invention enables preparing the effective vaccine for the disorders related to a reaction of the PCSK9 protein and its LDLR receptor.24 cl, 19 dwg, 6 tbl, 9 exИзобретение относится к области иммунологии и биотехнологии. Представлен иммуноген для индуцирования иммунного ответа против белка PCSK9, содержащий антигенный пептид PCSK9, выбранный из группы, состоящ
